NASDAQ · MDWD
MediWound financials
$13.80−0.93%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 | Q4 '22 Dec 31 | Q4 '21 Dec 31 | Q4 '20 Dec 31 | Q4 '19 Dec 31 | Q4 '18 Dec 31 | Q4 '17 Dec 31 | Q4 '16 Dec 31 | Q4 '15 Dec 31 | Q3 '15 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — | $267.0K | $102.0K |
| Gross profit | — | — | — | — | — | — | — | — | — | — | -$422.0K | -$722.0K |
| Gross margin | — | — | — | — | — | — | — | — | — | — | −158.1% | −707.8% |
| Operating income | — | — | — | — | — | — | — | — | — | — | -$6.8M | -$4.4M |
| Net income | — | — | — | — | — | — | — | — | — | — | -$7.8M | -$3.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | −2913.9% | −3692.2% |
| Diluted EPS | — | — | — | — | — | — | — | — | — | — | $-2.52 | $-1.19 |
| EBITDA | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$6.8M | -$4.2M |
| Operating cash flow | — | — | — | — | — | — | — | — | — | — | -$4.9M | -$5.3M |
| Free cash flow | — | — | — | — | — | — | — | — | — | — | -$5.0M | -$5.4M |
| Diluted shares | 11.4M | 10.0M | 9.0M | 5.0M | 3.9M | 3.9M | 3.9M | 3.9M | 3.3M | 21.9M | 3.1M | 3.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.8M | $9.2M | $11.9M | $33.9M | $11.0M | $17.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $870.0K | $612.0K | $1.4M | $2.2M | $2.4M | $2.4M |
| Total assets | $86.3M | $73.5M | $66.5M | $50.0M | $19.7M | $31.1M |
| Total liabilities | $42.6M | $42.3M | $34.9M | $39.1M | $24.3M | $23.8M |
| Shareholders' equity | $43.6M | $31.2M | $31.6M | $10.9M | -$4.6M | $7.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology